T. Rowe Price Associates
INBX icon

T. Rowe Price Associates’s Inhibrx INBX Stock Holding History

T. Rowe Price Associates’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$741K Buy
7,812
+800
+11% +$80.2K ﹤0.01% 2446
2026
Q1 		$472K Buy
7,012
+1,678
+31% +$124K ﹤0.01% 2486
2025
Q4 		$422K Buy
+5,334
New +$363K ﹤0.01% 2472

Other funds holding INBX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates's INBX Position: Q2 2026 in Review

T. Rowe Price Associates increased its Inhibrx (INBX) stake by 11% in Q2 2026, buying an estimated $80.2K and bringing the position to 7,812 shares worth $741K. The position accounts for ﹤0.01% of the portfolio, ranked #2446.

T. Rowe Price Associates first reported a position in INBX in Q4 2025 and has held it in 3 quarters since. 162 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • T. Rowe Price Associates held 7,812 shares of Inhibrx worth $741K as of Q2 2026.
  • T. Rowe Price Associates bought 800 Inhibrx shares in Q2 2026, an estimated $80.2K.
  • Inhibrx made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2446 holding.
  • T. Rowe Price Associates first reported a position in Inhibrx in Q4 2025 and has held it in 3 quarters since.
  • 162 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.